Sign In
Dr. Branimir I. Sikic, MD
About ProfilePoints™
0 Patient Reviews

Dr. Branimir I. Sikic, MD

Hematology / Oncology Specialist - Hematologist (Blood)

Highlights

  • Board Certified
  • Accepts Insurance Plans

Biography

Dr. Branimir I. Sikic, MD is a Hematology / Oncology Specialist - Hematologist (Blood) practicing in Palo Alto, CA

He has not yet shared a personalized biography with Doctor.com.

View Phone #Call Now

Are you Dr. Branimir I. Sikic, MD?

Claim your 100% free Doctor.com profile to:

  • Respond to patient reviews
  • Customize your profile
  • Improve your visibility to our millions of monthly users
Claim your profile

Provider Training

UniversityDegreeFocusGraduated
University of Chicago, Pritzker School of Medicine, Chicago IlOther Degree1972

InstitutionFocusYear
Internship - Georgetown University Hospital1973
Residency - Medstar-Georgetown Medical Center, Internal MedicineNot Specified
Residency - Georgetown University Hospital1975
Fellowship - National Cancer Institute1978

CertificationCert. BodyYear
Internal medicine
Sub-Specialty: Medical Oncology		Internal MedicineNot Specified

Sub-Specialty: Medical Oncology		Internal Medicine1979
Internal medicineInternal Medicine1975

Experience & Accolades

Publication Publisher Title Published
Other PublicationCLINICAL TRIALSClinical trial designs for testing biomarker-based persolized therapies2012
Other PublicationNEW ENGLAND JOURL OF MEDICINENFKBIA Deletion in Glioblastomas.2011
Other PublicationJAMA-JOURL OF THE AMERICAN MEDICAL ASSOCIATIONA Network Model of a Cooperative Genetic Landscape in Brain Tumors2009
Other PublicationJOURL OF CLINICAL ONCOLOGYDifferential gene expression patterns and interaction networks in BCR-ABL2007
Other PublicationGENES CHROMOSOMES & CANCERRegiol activation of chromosomal arm 7q with2006
Other PublicationINVESTIGATIOL NEW DRUGSPhase I study of gefitinib, oxaliplatin2006
Other PublicationJOURL OF CLINICAL ONCOLOGYTumor necrosis factor-alpha2006
Other PublicationPROCEEDINGS OF THE TIOL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMGene expression profiling differentiates germ cell tumors from other cancers2005
Other PublicationCANCER RESEARCHFunctiol network alysis reveals extended gliomagenesis pathway maps2005
Other PublicationJOURL OF CLINICAL ONCOLOGYPhase II study of gefitinib, fluorouracil2005
Other PublicationJourl of experimental therapeutics & oncologyModulation of resistance to idarubicin by the cyclosporin PSC 8332003
Other PublicationBRITISH JOURL OF CANCERMDR1 activation is the predomint resistance mechanism selected by vinblastine in MES-SA cells2000
Other PublicationONCOLOGY-NEW YORKModulation of multidrug resistance: A paradigm for translatiol clinical research1999
Other PublicationJOURL OF BIOLOGICAL CHEMISTRYMultidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype1997
Other PublicationJOURL OF THE TIOL CANCER INSTITUTEDECREASED MUTATION-RATE FOR CELLULAR1995
Other PublicationJOURL OF THE TIOL CANCER INSTITUTEMUTATION-RATES AND MECHANISMS OF RESISTANCE TO ETOPOSIDE DETERMINED FROM FLUCTUATION ALYSIS1994
Other PublicationJOURL OF CLINICAL ONCOLOGYPHASE-I TRIAL OF DOXORUBICIN WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG-RESISTANCE1994
Other PublicationJOURL OF CLINICAL ONCOLOGYMODULATION OF MULTIDRUG-RESISTANCE - AT THE THRESHOLD1993
Other PublicationJOURL OF CLINICAL ONCOLOGYPHASE-I TRIAL OF ETOPOSIDE WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG RESISTANCE1992
Other PublicationJOURL OF CLINICAL ONCOLOGYALTERATION OF ETOPOSIDE PHARMACOKINETICS AND PHARMACODYMICS BY CYCLOSPORINE IN A PHASE1992
Other PublicationSCIENCEDISSOCIATION OF ANTITUMOR POTENCY FROM ANTHRACYCLINE CARDIOTOXICITY IN A DOXORUBICIN ALOG1985
Other PublicationCANCER RESEARCHQUANTIFICATION OF BLEOMYCIN PULMORY TOXICITY IN MICE BY CHANGES IN LUNG HYDROXYPROLINE CONTENT1978
Other PublicationINVESTIGATIOL NEW DRUGSPhase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 32012
Other PublicationINVESTIGATIOL NEW DRUGSA phase I trial of vandetanib combined with capecitabine2012
Other PublicationINVESTIGATIOL NEW DRUGSPhase I trial of oblimersen (GesenseA (R)) and gemcitabine in refractory and advanced maligncies2011
Other PublicationANLS OF ONCOLOGYPhase I and pharmacokinetic study of lexatumumab2010
Other PublicationJOURL OF CLINICAL ONCOLOGYAlysis of phase II studies on targeted agents and subsequent phase III trials2008
Other PublicationUeda, S. M., Kapp, D. S., Sugiyama, V. E., Stave, C., Shin, J. Y., MonPredictors for success in a phase III trial2007
Other PublicationMethods in molecular biology (Clifton, N.J.)Integrated high-resolution genome-wide alysis of gene dosage2007
Other PublicationANLS OF ONCOLOGYA phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833)2005
Other PublicationINVESTIGATIOL NEW DRUGSA phase I trial of aprinocarsen (ISIS 35212005
Other PublicationFisher, G., Advani, R., Wakelee, H., Jacobs, C., Gladysheva, K., FitzgA phase I trial of oblimersen and gemcitabine in refractory and advanced maligncies2005
Other PublicationJOURL OF MOLECULAR DIAGNOSTICSAmplification of whole tumor genomes2005
Other PublicationJOURL OF CLINICAL ONCOLOGYMitoxantrone, etoposide2004
Other PublicationCANCERA phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kise C alpha2004
Other PublicationCho, C. D., Fisher, G. A., Halsey, J., Jambalos, C. N., Schwartz, E. JA phase II study of gefitinib in combition with FOLFOX-42003
Other PublicationCLINICAL CANCER RESEARCHPhase I and pharmacokinetic study of BMS-188797, a new taxane alog2003
Other PublicationBalzer, B., Schaner, M., Ross, D., Montgomery, K., Teng, N., Sikic, B.Protein expression study of ovarian surface epithelial neoplasms using tissue microarray alysis2003
Other PublicationJOURL OF CHROMATOGRAPHY B-ALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND Rapid determition of PEGylated liposomal doxorubicin2002
Other PublicationFisher, G. A., Cho, C. D., Halsey, J. Z., Advani, R. H., Yuen, A. R., A phase I study of ZD 1839 (Iressa) in combition with oxaliplatin2002
Other PublicationJOURL OF THE TIOL CANCER INSTITUTERe: Genetic alysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer2002
Other PublicationTURE GENETICSDomint effector genetics in mammalian cells2001
Other PublicationJOURL OF CLINICAL ONCOLOGYMitoxantrone, etoposide2000
Other PublicationANTI-CANCER DRUGSDecreased cortisol secretion by adrel gl2000
Other PublicationCANCER CHEMOTHERAPY AND PHARMACOLOGYEffect of high-dose cyclosporine on etoposide pharmacodymics in a trial to reverse P-glycoprotein2000
Other PublicationCLINICAL CANCER RESEARCHPhase I study of an antisense oligonucleotide to protein kise C-alpha (ISIS 35211999
Other PublicationJOURL OF CLINICAL ONCOLOGYMechanisms of action of and resistance to antitubulin agents: Microtubule dymics, drug transport1999
Other PublicationBLOODTreatment of refractory1999
Other PublicationJOURL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMESInteraction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein1998
Other PublicationSEMIRS IN HEMATOLOGYPharmacologic approaches to reversing multidrug resistance1997
Other PublicationANLS OF ONCOLOGYTreatment of angioimmunoblastic T-cell lymphoma with cyclosporine1997
Other PublicationBRITISH JOURL OF CANCERSpontaneous overexpression of the long form of the bcl1997
Other PublicationCANCER CHEMOTHERAPY AND PHARMACOLOGYDifferential single- versus double1996
Other PublicationEUROPEAN JOURL OF CANCERPharmacological considerations in the modulation of multidrug resistance1996
Other PublicationAMERICAN JOURL OF PHYSIOLOGY-CELL PHYSIOLOGYDoxorubicin selection for MDR11996
Other PublicationBIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCHINHIBITION OF LYSOSOMAL ACID SPHINGOMYELISE BY AGENTS WHICH REVERSE MULTIDRUG-RESISTANCE1995
Other PublicationMOLECULAR PHARMACOLOGYEVIDENCE FOR TRANSCRIPTIOL CONTROL OF HUMAN MDR1 GENE-EXPRESSION BY VERAPAMIL IN MULTIDRUG1995
Other PublicationINTERTIOL JOURL OF ONCOLOGYALYSIS OF INTRACELLULAR RETENTION OF MORPHOLINYL ANTHRACYCLINES IN MULTIDRUG-RESISTANT CANCER1994
Other PublicationJOURL OF CLINICAL ONCOLOGYMULTIDRUG-RESISTANCE IN LYMPHOMAS1994
Other PublicationBRITISH JOURL OF CANCERMETABOLIC CONVERSION OF METHOXYMORPHOLINYL DOXORUBICIN - FROM A D STRAND BREAKER TO A D CROSS1994
Other PublicationLum, B. L., Fisher, G. A., BROPHY, N. A., Yahanda, A. M., ADLER, K. M.CLINICAL-TRIALS OF MODULATION OF MULTIDRUG1993
Other PublicationJOURL OF THE TIOL CANCER INSTITUTECHARACTERIZATION OF COVALENT D-BINDING OF MORPHOLINO AND CYANOMORPHOLINO DERIVATIVES OF DOXORUBICIN1992
Other PublicationEXPERIMENTAL HEMATOLOGYUSE OF ETOPOSIDE IN COMBITION WITH CYCLOSPORINE FOR PURGING MULTIDRUG-RESISTANT LEUKEMIC1992
Other PublicationBRITISH JOURL OF HAEMATOLOGYEXPRESSION OF MULTIDRUG RESISTANCE GENE MDR1 MESSENGER-R IN A SUBSET OF NORMAL BONE-MARROW CELLS1992
Other PublicationProgress in clinical and biological researchUse of etoposide in combition with cyclosporine1992
Other PublicationCLINICAL TRIALSClinical trial designs for testing biomarker-based personalized therapies2012
Other PublicationNEW ENGLAND JOURNAL OF MEDICINENFKBIA Deletion in Glioblastomas.2011
Other PublicationMOLECULAR CANCER THERAPEUTICSExpression and Silencing of the Microtubule-Associated Protein Tau in Breast Cancer Cells2010
Other PublicationJAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATIONA Network Model of a Cooperative Genetic Landscape in Brain Tumors2009
Other PublicationCLINICAL CANCER RESEARCHA Phase II Study of Gefitinib, 5-Fluorouracil2008
Other PublicationJOURNAL OF CLINICAL ONCOLOGYDifferential gene expression patterns and interaction networks in BCR-ABL2007
Other PublicationGENES CHROMOSOMES & CANCERRegional activation of chromosomal arm 7q with2006
Other PublicationINVESTIGATIONAL NEW DRUGSPhase I study of gefitinib, oxaliplatin2006
Other PublicationJOURNAL OF CLINICAL ONCOLOGYTumor necrosis factor-alpha2006
Other PublicationPROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OGene expression profiling differentiates germ cell tumors from other cancers2005
Other PublicationCANCER RESEARCHGenetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell2005
Other PublicationCANCER RESEARCHFunctional network analysis reveals extended gliomagenesis pathway maps2005
Other PublicationJOURNAL OF CLINICAL ONCOLOGYPhase II study of gefitinib, fluorouracil2005
Other PublicationCANCER RESEARCHHigh-resolution genome-wide mapping of genetic alterations in human glial brain tumors2005
Other PublicationBLOODGene expression profiles at diagnosis2004
Other PublicationMOLECULAR PHARMACOLOGYCCAAT/enhancer-binding protein beta (nuclear factor for interleukin 6) transactivates the human2004
Other PublicationJournal of experimental therapeutics & oncologyModulation of resistance to idarubicin by the cyclosporin PSC 8332003
Other PublicationGENES CHROMOSOMES & CANCERPreferential expression of a mutant allele of the amplified MDR12002
Other PublicationBRITISH JOURNAL OF CANCERMDR1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells2000
Other PublicationMOLECULAR PHARMACOLOGYLoss of cyclosporin2000
Other PublicationONCOLOGY-NEW YORKModulation of multidrug resistance: A paradigm for translational clinical research1999
Other PublicationCANCER CHEMOTHERAPY AND PHARMACOLOGYModulation and prevention of multidrug resistance by inhibitors of P-glycoprotein1997
Other PublicationJOURNAL OF BIOLOGICAL CHEMISTRYMultidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype1997
Other PublicationCANCER RESEARCHResistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel1996
Other PublicationJOURNAL OF THE NATIONAL CANCER INSTITUTEDECREASED MUTATION-RATE FOR CELLULAR1995
Other PublicationCancer treatment and researchThe reversal of multidrug resistance.1995
Other PublicationCANCER RESEARCHPREVALENCE OF MULTIDRUG1994
Other PublicationJOURNAL OF THE NATIONAL CANCER INSTITUTEMUTATION-RATES AND MECHANISMS OF RESISTANCE TO ETOPOSIDE DETERMINED FROM FLUCTUATION ANALYSIS1994
Other PublicationJOURNAL OF CLINICAL ONCOLOGYPHASE-I TRIAL OF DOXORUBICIN WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG-RESISTANCE1994
Other PublicationJOURNAL OF CLINICAL ONCOLOGYMODULATION OF MULTIDRUG-RESISTANCE - AT THE THRESHOLD1993
Other PublicationJOURNAL OF CLINICAL ONCOLOGYPHASE-I TRIAL OF ETOPOSIDE WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG RESISTANCE1992
Other PublicationJOURNAL OF CLINICAL ONCOLOGYALTERATION OF ETOPOSIDE PHARMACOKINETICS AND PHARMACODYNAMICS BY CYCLOSPORINE IN A PHASE1992
Other PublicationBLOODMULTIDRUG RESISTANCE1991
Other PublicationCANCER RESEARCHMULTIDRUG (PLEIOTROPIC) RESISTANCE IN DOXORUBICIN1985
Other PublicationSCIENCEDISSOCIATION OF ANTITUMOR POTENCY FROM ANTHRACYCLINE CARDIOTOXICITY IN A DOXORUBICIN ANALOG1985
Other PublicationCANCER RESEARCHDEVELOPMENT AND CHARACTERIZATION OF A HUMAN SARCOMA CELL-LINE, MES-SA, SENSITIVE TO MULTIPLE-DRUGS1983
Other PublicationCANCER TREATMENT REPORTSIMPROVED THERAPEUTIC INDEX OF BLEOMYCIN WHEN ADMINISTERED BY CONTINUOUS INFUSION IN MICE1978
Other PublicationCANCER RESEARCHQUANTIFICATION OF BLEOMYCIN PULMONARY TOXICITY IN MICE BY CHANGES IN LUNG HYDROXYPROLINE CONTENT1978
Other PublicationINVESTIGATIONAL NEW DRUGSPhase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 32012
Other PublicationINVESTIGATIONAL NEW DRUGSA phase I trial of vandetanib combined with capecitabine2012
Other PublicationINVESTIGATIONAL NEW DRUGSPhase I trial of oblimersen (GenasenseA (R)) and gemcitabine2011
Other PublicationPEDIATRIC BLOOD & CANCERPhase I Study of Valspodar2010
Other PublicationANNALS OF ONCOLOGYPhase I and pharmacokinetic study of lexatumumab2010
Other PublicationJOURNAL OF CLINICAL ONCOLOGYAnalysis of phase II studies on targeted agents and subsequent phase III trials2008
Other PublicationUeda, S. M., Kapp, D. S., Sugiyama, V. E., Stave, C., Shin, J. Y., MonPredictors for success in a phase III trial2007
Other PublicationMethods in molecular biology (Clifton, N.J.)Integrated high-resolution genome-wide analysis of gene dosage2007
Other PublicationLacayo, N. J., O'Brien, M., Jain, S., Meshinchi, S., Yu, R., Juric, D.Gene expression profiling predicts outcome in de novo acute myeloid leukemia2006
Other PublicationJuric, D., Lacayo, N. J., Ramsey, M. C., Racevskis, J., Wiernik, P. H.Differential gene expression patterns and interaction networks in BCR2006
Other PublicationCANCER INVESTIGATIONA pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel2006
Other PublicationCLINICAL CANCER RESEARCHMultidrug resistance and stem cells in acute myeloid leukemia2006
Other PublicationANNALS OF ONCOLOGYA phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833)2005
Other PublicationLacayo, N., Meshinchi, S., Raimondi, S., Saraiya, C., O'Brien, M., Yu,Gene expression profiling and FLT3 status correlate with outcome in de novo acute myeloid leukemia2005
Other PublicationINVESTIGATIONAL NEW DRUGSA phase I trial of aprinocarsen (ISIS 35212005
Other PublicationCLINICAL LUNG CANCERActivity of novel cytotoxic agents in lung cancer: Epothilones and topoisomerase I inhibitors2005
Other PublicationFisher, G., Advani, R., Wakelee, H., Jacobs, C., Gladysheva, K., FitzgA phase I trial of oblimersen and gemcitabine in refractory and advanced malignancies2005
Other PublicationJOURNAL OF MOLECULAR DIAGNOSTICSAmplification of whole tumor genomes2005
Other PublicationBMC GENOMICSA method for detecting and correcting feature misidentification on expression microarrays2004
Other PublicationBulletin du cancerResistance to microtubule2004
Other PublicationJOURNAL OF CLINICAL ONCOLOGYMitoxantrone, etoposide2004
Other PublicationLANCET ONCOLOGYGenomics-based hypothesis generation2004
Other PublicationCANCERA phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha2004
Other PublicationCho, C. D., Fisher, G. A., Halsey, J., Jambalos, C. N., Schwartz, E. JA phase II study of gefitinib in combination with FOLFOX-42003
Other PublicationCLINICAL CANCER RESEARCHPhase I and pharmacokinetic study of BMS-188797, a new taxane analog2003
Other PublicationMOLECULAR BIOLOGY OF THE CELLGene expression patterns in ovarian carcinomas2003
Other PublicationBREAST CANCER RESEARCH AND TREATMENTPhase I trial of uracil-ftorafur, leucovorin2003
Other PublicationBalzer, B., Schaner, M., Ross, D., Montgomery, K., Teng, N., Sikic, B.Protein expression study of ovarian surface epithelial neoplasms using tissue microarray analysis2003
Other PublicationJOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL Rapid determination of PEGylated liposomal doxorubicin2002
Other PublicationFisher, G. A., Cho, C. D., Halsey, J. Z., Advani, R. H., Yuen, A. R., A phase I study of ZD 1839 (Iressa) in combination with oxaliplatin2002
Other PublicationJOURNAL OF THE NATIONAL CANCER INSTITUTERe: Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer2002
Other PublicationLEUKEMIAPharmacokinetic interactions of cyclosporine with etoposide2002
Other PublicationLum, B. L., Chin, D. L., Cho, C. D., Advani, R., Fisher, G. A., HalseyThe effect of oral valspodar (psc 833), a modulator of multidrug resistance2002
Other PublicationMOLECULAR CANCER THERAPEUTICSConservation of the class I beta-tubulin gene in human populations2002
Other PublicationCLINICAL CANCER RESEARCHMotexafin gadolinium: A redox active drug that enhances the efficacy of bleomycin and doxorubicin2001
Other PublicationAdvani, R., Fisher, G. A., Lum, B. L., Hausdorff, J., Halsey, J., LitcA phase I trial of doxorubicin, paclitaxel2001
Other PublicationNATURE GENETICSDominant effector genetics in mammalian cells2001
Other PublicationFRONTIERS IN BIOSCIENCEClinical studies of antisense therapy in cancer2000
Other PublicationJOURNAL OF CLINICAL ONCOLOGYMitoxantrone, etoposide2000
Other PublicationANTI-CANCER DRUGSDecreased cortisol secretion by adrenal gl2000
Other PublicationCANCER CHEMOTHERAPY AND PHARMACOLOGYEffect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P2000
Other PublicationGreenberg, P., Advani, R., Tallman, M., Letendre, L., Saba, H., Dugan,Treatment of refractory1999
Other PublicationCLINICAL CANCER RESEARCHPhase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 35211999
Other PublicationJOURNAL OF CLINICAL ONCOLOGYMechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport1999
Other PublicationBLOODTreatment of refractory1999
Other PublicationTallman, M. S., Lee, S., Sikic, B. I., Paietta, E., Wiernik, P. H., BeMitoxantrone, etoposide1999
Other PublicationAdvani, R., Visani, G., Milligan, D., Saba, H., Tallman, M., Rowe, J. Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide1999
Other PublicationSikic, B. I.New approaches in cancer treatment1999
Other PublicationJOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMESInteraction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein1998
Other PublicationCANCER CHEMOTHERAPY AND PHARMACOLOGYEffect of the multidrug resistance modulator valspodar on serum cortisol levels in rabbits1998
Other PublicationSEMINARS IN HEMATOLOGYPharmacologic approaches to reversing multidrug resistance1997
Other PublicationPHARMACOTHERAPYValidation of a limited sampling model to determine etoposide area under the curve1997
Other PublicationANNALS OF ONCOLOGYTreatment of angioimmunoblastic T-cell lymphoma with cyclosporine1997
Other PublicationBRITISH JOURNAL OF CANCERSpontaneous overexpression of the long form of the bcl1997
Other PublicationCANCER CHEMOTHERAPY AND PHARMACOLOGYDifferential single- versus double1996
Other PublicationEUROPEAN JOURNAL OF CANCERPharmacological considerations in the modulation of multidrug resistance1996
Other PublicationAMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGYDoxorubicin selection for MDR11996
Other PublicationLum, B. L., Synold, T. W., Lane, K., Charnick, S. B., Sikic, B. I.Neural network (NN)1996
Other PublicationCELL MOTILITY AND THE CYTOSKELETONDifferential expression of tubulin isotypes during the cell cycle1996
Other PublicationCANCER CHEMOTHERAPY AND PHARMACOLOGYEffect of different mathematical methods on etoposide area under the curve estimations1996
Other PublicationLEUKEMIAGLUTATHIONE-S-TRANSFERASE-PI, GLUTATHIONE-S-TRANSFERASE-ALPHA1995
Other PublicationANTI-CANCER DRUGSCYCLOSPORINE-A INCREASES SERUM CORTISOL-LEVELS IN RABBITS1995
Other PublicationBIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCHINHIBITION OF LYSOSOMAL ACID SPHINGOMYELINASE BY AGENTS WHICH REVERSE MULTIDRUG-RESISTANCE1995
Other PublicationHematology/oncology clinics of North AmericaDrug resistance in clinical oncology and hematology. Introduction.1995
Other PublicationHEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICACLINICAL-STUDIES WITH MODULATORS OF MULTIDRUG-RESISTANCE1995
Other PublicationONCOLOGY RESEARCHNovel mechanism of resistance to paclitaxel (Taxol(R))1995
Other PublicationMOLECULAR PHARMACOLOGYEVIDENCE FOR TRANSCRIPTIONAL CONTROL OF HUMAN MDR1 GENE-EXPRESSION BY VERAPAMIL IN MULTIDRUG1995
Other PublicationINTERNATIONAL JOURNAL OF ONCOLOGYANALYSIS OF INTRACELLULAR RETENTION OF MORPHOLINYL ANTHRACYCLINES IN MULTIDRUG-RESISTANT CANCER1994
Other PublicationJOURNAL OF CLINICAL ONCOLOGYMULTIDRUG-RESISTANCE IN LYMPHOMAS1994
Other PublicationCANCER RESEARCHVOLUME-ACTIVATED CHLORIDE CURRENT IS NOT RELATED TO P-GLYCOPROTEIN OVEREXPRESSION1994
Other PublicationBRITISH JOURNAL OF CANCERMETABOLIC CONVERSION OF METHOXYMORPHOLINYL DOXORUBICIN - FROM A DNA STRAND BREAKER TO A DNA CROSS1994
Other PublicationLEUKEMIAMDR1 GENE-EXPRESSION IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIAS AND LYMPHOMAS1994
Other PublicationBLOODCYCLOSPORINE A AND CYCLOSPORINE SDZ PSC 833 ENHANCE ANTI-CD5 RICIN A1994
Other PublicationCancer treatment and researchClinical reversal of multidrug resistance.1994
Other PublicationLEYLANDJONES, B., Dalton, W., Fisher, G. A., Sikic, B. I.REVERSAL OF MULTIDRUG-RESISTANCE TO CANCER-CHEMOTHERAPY1993
Other PublicationLum, B. L., Fisher, G. A., BROPHY, N. A., Yahanda, A. M., ADLER, K. M.CLINICAL-TRIALS OF MODULATION OF MULTIDRUG1993
Other PublicationCANCER CHEMOTHERAPY AND PHARMACOLOGYEFFECTS OF THE METHOXYMORPHOLINO DERIVATIVE OF DOXORUBICIN AND ITS BIOACTIVATED FORM VERSUS1993
Other PublicationPHARMACOTHERAPYMOLECULAR TARGETS IN ONCOLOGY - IMPLICATIONS OF THE MULTIDRUG RESISTANCE GENE1993
Other PublicationFisher, G. A., BROPHY, N. A., Yahanda, A. M., Adler, K. A., Lum, B. L.THE MODULATION OF MULTIDRUG-RESISTANCE - CLINICAL-STUDIES AT STANFORD1993
Other PublicationJOURNAL OF THE NATIONAL CANCER INSTITUTECHARACTERIZATION OF COVALENT DNA1992
Other PublicationEXPERIMENTAL HEMATOLOGYUSE OF ETOPOSIDE IN COMBINATION WITH CYCLOSPORINE FOR PURGING MULTIDRUG-RESISTANT LEUKEMIC1992
Other PublicationCANCER RESEARCHROLE OF CYTOCHROME-P1992
Other PublicationBRITISH JOURNAL OF HAEMATOLOGYEXPRESSION OF MULTIDRUG RESISTANCE GENE MDR1 MESSENGER-RNA IN A SUBSET OF NORMAL BONE-MARROW CELLS1992
Other PublicationProgress in clinical and biological researchUse of etoposide in combination with cyclosporine1992
Other PublicationSikic, B. I.COMBINED CHEMOTHERAPY AND RADIOTHERAPY FOR ADVANCED-STAGE CARCINOMAS OF THE CERVIX1992
Other PublicationProgress in clinical and biological researchPurging multidrug resistant cells from bone marrow.

Practice & Hospital Affiliations

Dr. Branimir I. Sikic, MD has not yet indicated the hospitals that he is affiliated with.

Photos

Provider Profile 0

Specialties

Languages Spoken
English
Medical Specialties
  • Hematology / Oncology Specialist - Sub-Specialty: Hematologist (Blood)

Years In Practice: 46 (started in 1979)

Accepts New Patients: Yes

Accepted Insurance

Full Insurance List

Payment Options

Payment Details
We use cookies and limited processing of your personal information for our website and services to function. By using our site, you agree to our use of cookies and our privacy policy.
I Accept